Vera Therapeutics, Inc. (VERA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$27.99-3.65%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Vera Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	18.55M
EPS	—	-1.457
Annual ending 2026-12-31
Revenue	—	24.85M
EPS	—	-6.241
Annual ending 2027-12-31
Revenue	—	233.77M
EPS	—	-4.249

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Control of operating losses and cash burn	The company is focused on controlling its operating losses and cash burn despite current challenges.	Under Pressure	Net losses and cash burn exceed $100M per quarter persistently beyond FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Operating losses increased from $83.9M in 2025-Q3 to $112.5M in 2026-Q2, with net losses rising from $80.3M to $109.5M over the same period. Management notes a strong balance sheet to fund operations, but financials show increasing losses, indicating limited progress in reducing cash burn. Delivery assessment Oct 24, 2026
FDA approval progress for Atacicept in IgA Nephropathy	Vera Therapeutics is advancing its key drug Atacicept toward full FDA approval, which could unlock significant value.	Improving	FDA delays or denies full approval beyond next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth from clinical program progress	A supporting condition in Vera Therapeutics, Inc.'s published investment case. The stated target is Revenue grows toward $253.5M by FY27.	Intact	Revenue fails to grow beyond $38M in FY26 and declines thereafter	Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue grows toward $253.5M by FY27. Target period is not explicitly aligned with this observation. Source published Aug 10, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.25

$-3.91 → $-4.25 · observed estimates

FY2027 revenue$0.23B

$0.26B → $0.23B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.91	$261,096,287	8 / 8
2026-07-25	$-3.86	$261,074,200	8 / 11
2026-07-26	$-3.86	$261,074,200	8 / 11
2026-07-27	$-3.86	$261,074,200	8 / 11
2026-07-28	$-3.86	$261,074,200	8 / 11
2026-07-29	$-3.91	$261,096,287	8 / 8
2026-07-30	$-3.86	$261,074,200	8 / 11
2026-07-31	$-3.91	$261,096,287	8 / 8
2026-08-01	$-3.91	$261,096,287	8 / 8
2026-08-02	$-3.91	$261,096,287	8 / 8
2026-08-03	$-3.91	$261,096,287	8 / 8
2026-08-04	$-3.86	$261,074,200	8 / 11
2026-08-05	$-3.86	$261,074,200	8 / 11
2026-08-06	$-3.86	$261,074,200	8 / 11
2026-08-08	$-3.86	$261,074,200	8 / 11
2026-08-09	$-3.86	$261,074,200	8 / 11
2026-08-10	$-3.91	$261,100,104	8 / 8
2026-08-12	$-3.91	$261,100,104	8 / 8
2026-08-13	$-3.91	$261,100,104	8 / 8
2026-08-14	$-3.91	$261,100,104	8 / 8
2026-08-15	$-3.91	$261,100,104	8 / 8
2026-08-16	$-3.91	$261,100,104	8 / 8
2026-08-17	$-3.91	$261,100,104	8 / 8
2026-08-18	$-3.91	$261,100,104	8 / 8
2026-08-19	$-3.91	$261,100,104	8 / 8
2026-08-20	$-4.28	$234,896,368	8 / 8
2026-08-21	$-4.28	$234,896,368	8 / 8
2026-08-22	$-4.28	$234,896,368	8 / 8
2026-08-23	$-4.28	$234,896,368	8 / 8
2026-08-24	$-4.28	$234,896,368	8 / 8
2026-08-25	$-4.28	$234,896,368	8 / 8
2026-08-26	$-4.28	$234,896,368	8 / 8
2026-08-27	$-4.28	$234,896,368	8 / 8
2026-08-28	$-4.28	$234,896,368	8 / 8
2026-08-29	$-4.28	$234,896,368	8 / 8
2026-08-30	$-4.28	$234,896,368	8 / 8
2026-08-31	$-4.28	$234,896,368	8 / 8
2026-09-01	$-4.45	$220,205,459	8 / 8
2026-09-02	$-4.45	$220,205,459	8 / 8
2026-09-03	$-4.45	$220,209,277	8 / 8
2026-09-04	$-4.45	$220,209,277	8 / 8
2026-09-05	$-4.45	$220,209,277	8 / 8
2026-09-06	$-4.45	$220,209,277	8 / 8
2026-09-07	$-4.45	$220,209,277	8 / 8
2026-09-08	$-4.43	$221,239,238	8 / 8
2026-09-09	$-4.43	$221,212,944	8 / 8
2026-09-10	$-4.43	$221,212,944	8 / 8
2026-09-11	$-4.43	$221,212,944	8 / 8
2026-09-12	$-4.43	$221,212,944	8 / 8
2026-09-13	$-4.43	$221,212,944	8 / 8
2026-09-14	$-4.43	$221,212,944	9 / 8
2026-09-15	$-4.43	$221,212,944	9 / 8
2026-09-16	$-4.43	$221,212,944	9 / 8
2026-09-17	$-4.43	$221,212,944	9 / 8
2026-09-18	$-4.43	$221,212,944	9 / 8
2026-09-19	$-4.43	$221,212,944	9 / 8
2026-09-20	$-4.43	$221,212,944	9 / 8
2026-09-21	$-4.43	$221,212,944	9 / 8
2026-09-22	$-4.43	$221,212,944	9 / 8
2026-09-23	$-4.43	$221,212,944	9 / 8
2026-09-24	$-4.43	$221,212,944	9 / 8
2026-09-25	$-4.43	$221,212,944	9 / 8
2026-09-26	$-4.43	$221,212,944	9 / 8
2026-09-27	$-4.43	$221,212,944	9 / 8
2026-09-28	$-4.43	$221,212,944	9 / 8
2026-09-29	$-4.43	$221,212,944	9 / 8
2026-09-30	$-4.43	$221,212,944	9 / 8
2026-10-01	$-4.43	$221,212,944	9 / 8
2026-10-02	$-4.43	$221,212,944	9 / 8
2026-10-03	$-4.35	$221,212,944	9 / 8
2026-10-04	$-4.35	$221,212,944	9 / 8
2026-10-05	$-4.35	$221,212,944	9 / 8
2026-10-06	$-4.35	$221,212,944	9 / 8
2026-10-07	$-4.35	$221,212,944	9 / 8
2026-10-08	$-4.35	$221,212,944	9 / 8
2026-10-09	$-4.26	$230,700,035	9 / 8
2026-10-10	$-4.26	$230,700,035	9 / 8
2026-10-11	$-4.27	$228,704,834	9 / 8
2026-10-12	$-4.27	$228,704,834	9 / 8
2026-10-13	$-4.25	$232,371,097	9 / 9
2026-10-14	$-4.25	$232,371,097	9 / 9
2026-10-15	$-4.25	$232,371,097	9 / 9
2026-10-16	$-4.25	$232,371,097	9 / 9
2026-10-17	$-4.25	$232,371,097	9 / 9
2026-10-18	$-4.25	$232,371,097	9 / 9
2026-10-19	$-4.25	$232,371,097	9 / 9
2026-10-20	$-4.25	$233,769,664	9 / 9
2026-10-21	$-4.25	$233,769,664	9 / 9
2026-10-22	$-4.25	$233,769,664	9 / 9
2026-10-23	$-4.25	$233,768,114	9 / 9
2026-10-24	$-4.25	$233,768,114	9 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	1
2026-06-01	13	1
2026-07-01	13	1
2026-08-01	13	1
2026-09-01	13	1
2026-10-01	13	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Leerink PartnersOct 12

$34.00New observation · no comparable prior

$0$18.70$37.40

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Control of operating losses and cash burnPublished status: Under Pressure
FDA approval progress for Atacicept in IgA NephropathyDirect metric needs a verified mapping
Revenue growth from clinical program progressRevenue: $0

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-52.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Vera Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk biotechnology business, not yet a proven earnings compounder, because the evidence classifies it as loss-making. The long-term thesis is in a watch state: management has delivered key trial and launch milestones, while recent financial performance remains weak.

What's priced into Vera Therapeutics, Inc.

The evidence gives no valuation multiple or peer comparison, so whether VERA is cheap, fair, or expensive cannot be assessed. No priced-in fragility gates fired, but that does not show what expectations the market already assumes.

What the fundamentals likely do

Near term, the U.S. TRUTAKNA launch has early signs of uptake, and the ORIGIN 3 final analysis confirmed trial success. Supplemental filing and potential full-approval milestones remain ahead, while the company is still loss-making and its recent financial performance trails its industry cohort. The next results carry meaningful execution risk, with a stated miss probability of 42%.

What Vera Therapeutics, Inc. hinges on

Over the next one to three years, the thesis hinges on whether launch momentum develops into durable commercial progress and whether pending regulatory milestones support broader approval. Guidance cuts or further weak labor data could weigh on the near-term setup; continued strength among healthcare peers could provide a sector tailwind. Evidence confidence is low, so these signals remain uncertain.